Cytosorbents Corp
No SEC Form 4 filings for $CTSO in the last 30 days.
See all $CTSO insider activity →WBB Securities initiated coverage on CytoSorbents (CTSO) with a Speculative Buy rating and $9.50 price target, citing business restructuring and expected profitability in 2027. The company reported $9.6M Q2 2026 revenue, a 73% gross margin, and improved operating losses. Analysts predict profitability this year, supporting a turnaround thesis.
CytoSorbents (CTSO) announced it regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company's stock closed at or above this price for 10 consecutive trading sessions. CytoSorbents is also working to meet other Nasdaq listing requirements by December 28, 2026. The company aims to drive sales, achieve cash flow breakeven, and advance regulatory approvals for its products.
Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CTSO (Cytosorbents Corp). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CTSO coverage spans insider activity, earnings and corporate actions.
Analyst initiates coverage with a Speculative Buy and a $9.50 price target, implying significant upside.
Regaining compliance may stabilize share price and prevent delisting risk.
Regaining compliance may stabilize the stock and prevent delisting, supporting short-term price support.
The purchase is small relative to the company's market cap and unlikely to move the stock.
Small insider purchase may signal confidence but size is negligible for price impact.
AlphAI scores every news story that mentions CTSO with an AI model for sentiment and relevance, and aggregates insider trades from Cytosorbents Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
WBB Securities initiated coverage on CytoSorbents (CTSO) with a Speculative Buy rating and $9.50 price target, citing business restructuring and expected profitability in 2027. The company reported $9.6M Q2 2026 revenue, a 73% gross margin, and improved operating losses. Analysts predict profitability this year, supporting a turnaround thesis.
2 min readCytoSorbents (CTSO) announced it regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company's stock closed at or above this price for 10 consecutive trading sessions. CytoSorbents is also working to meet other Nasdaq listing requirements by December 28, 2026. The company aims to drive sales, achieve cash flow breakeven, and advance regulatory approvals for its products.
1 min readCytosorbents Corp (CTSO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo
1 min readChan Phillip P. (Chief Executive Officer) purchased 3,774 shares of Cytosorbents Corp (CTSO) at $6.00 on 2026-09-15.
1 min readCapponi Vincent (President and COO) purchased 2,073 shares of Cytosorbents Corp (CTSO) at an average of $6.05 ($5.90–$6.07) across 2 trades on 2026-09-14.
1 min readSobel Alan D. purchased 2,500 shares of Cytosorbents Corp (CTSO) at an average of $6.10 ($6.01–$6.12) across 3 trades on 2026-09-15.
1 min readChan Phillip P. (Chief Executive Officer) purchased 200,000 shares of Cytosorbents Corp (CTSO) at $0.35 on 2026-09-04.
1 min readCytosorbents Corp (CTSO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders CytoSorbents Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on August 13, 2026. At the Annual Meeting, the following matters were submitted to a vote of stockholders: 1.
3 min readCytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.
6 min readCytoSorbents (NASDAQ: CTSO) reported Q2 2026 revenue of $9.6 million, unchanged year over year. Gross margin rose to 73%. Operating loss fell 27% to $2.6 million, and net loss was $4.4 million ($0.07/share). Adjusted net loss improved 22% to $2.8 million. Cash burn was $0.4 million. The company also discussed sales trends and FDA regulatory plans.
6 min read
